-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Reviewing HCW Biologics (NASDAQ:HCWB) and MoonLake Immunotherapeutics (NASDAQ:MLTX)
Reviewing HCW Biologics (NASDAQ:HCWB) and MoonLake Immunotherapeutics (NASDAQ:MLTX)
HCW Biologics (NASDAQ:HCWB – Get Rating) and MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, risk, institutional ownership, earnings and analyst recommendations.
Analyst Ratings
This is a breakdown of current ratings and target prices for HCW Biologics and MoonLake Immunotherapeutics, as reported by MarketBeat.com.
Get HCW Biologics alerts:Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
HCW Biologics | 0 | 0 | 2 | 0 | 3.00 |
MoonLake Immunotherapeutics | 0 | 0 | 5 | 0 | 3.00 |
HCW Biologics currently has a consensus price target of $6.00, suggesting a potential upside of 192.68%. MoonLake Immunotherapeutics has a consensus price target of $20.33, suggesting a potential upside of 106.85%. Given HCW Biologics' higher probable upside, research analysts clearly believe HCW Biologics is more favorable than MoonLake Immunotherapeutics.
Profitability
This table compares HCW Biologics and MoonLake Immunotherapeutics' net margins, return on equity and return on assets.Net Margins | Return on Equity | Return on Assets | |
HCW Biologics | N/A | -27.12% | -25.26% |
MoonLake Immunotherapeutics | N/A | 19.69% | 7.17% |
Institutional & Insider Ownership
1.6% of HCW Biologics shares are held by institutional investors. 44.0% of HCW Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Risk & Volatility
HCW Biologics has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.
Earnings & Valuation
This table compares HCW Biologics and MoonLake Immunotherapeutics' gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
HCW Biologics | $4.10 million | 17.94 | -$12.86 million | N/A | N/A |
MoonLake Immunotherapeutics | N/A | N/A | -$4.54 million | N/A | N/A |
MoonLake Immunotherapeutics has lower revenue, but higher earnings than HCW Biologics.
Summary
MoonLake Immunotherapeutics beats HCW Biologics on 5 of the 9 factors compared between the two stocks.
About HCW Biologics
(Get Rating)
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
About MoonLake Immunotherapeutics
(Get Rating)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
HCW Biologics (NASDAQ:HCWB – Get Rating) and MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, risk, institutional ownership, earnings and analyst recommendations.
虎威生物(納斯達克:HCWB-GET評級)和月湖免疫治療(納斯達克:MLTX-GET評級)都是小盤醫療公司,但哪一項業務更優越?我們將根據這兩家公司的估值、盈利能力、股息、風險、機構所有權、收益和分析師建議的強弱對它們進行比較。
Analyst Ratings
分析師評級
This is a breakdown of current ratings and target prices for HCW Biologics and MoonLake Immunotherapeutics, as reported by MarketBeat.com.
據MarketBeat.com報道,這是HCW Biologics和MoonLake免疫療法的當前評級和目標價格的細目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
HCW Biologics | 0 | 0 | 2 | 0 | 3.00 |
MoonLake Immunotherapeutics | 0 | 0 | 5 | 0 | 3.00 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
HCW生物製品 | 0 | 0 | 2 | 0 | 3.00 |
月湖免疫療法 | 0 | 0 | 5 | 0 | 3.00 |
HCW Biologics currently has a consensus price target of $6.00, suggesting a potential upside of 192.68%. MoonLake Immunotherapeutics has a consensus price target of $20.33, suggesting a potential upside of 106.85%. Given HCW Biologics' higher probable upside, research analysts clearly believe HCW Biologics is more favorable than MoonLake Immunotherapeutics.
HCW Biologics目前的一致目標價為6.00美元,暗示潛在上漲192.68%。MoonLake免疫療法公司的一致目標價為20.33美元,暗示潛在上漲106.85%。鑑於HCW Biologics更有可能上行,研究分析師顯然認為HCW Biologics比MoonLake免疫療法更有利。
Profitability
盈利能力
Net Margins | Return on Equity | Return on Assets | |
HCW Biologics | N/A | -27.12% | -25.26% |
MoonLake Immunotherapeutics | N/A | 19.69% | 7.17% |
淨利潤率 | 股本回報率 | 資產回報率 | |
HCW生物製品 | 不適用 | -27.12% | -25.26% |
月湖免疫療法 | 不適用 | 19.69% | 7.17% |
Institutional & Insider Ownership
機構與內部人持股
1.6% of HCW Biologics shares are held by institutional investors. 44.0% of HCW Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
HCW Biologics 1.6%的股份由機構投資者持有。HCW Biologics 44.0%的股份由公司內部人士持有。強大的機構持股表明,對衝基金、捐贈基金和大型基金管理公司相信,一家公司的長期表現將好於大盤。
Risk & Volatility
風險與波動性
HCW Biologics has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.
HCW Biologics的貝塔係數為0.94,表明其股價的波動性比標準普爾500指數低6%。相比之下,MoonLake免疫療法的貝塔係數為1.27,這表明其股價的波動性比標準普爾500指數高27%。
Earnings & Valuation
收益與估值
This table compares HCW Biologics and MoonLake Immunotherapeutics' gross revenue, earnings per share and valuation.
此表比較了HCW Biologics和MoonLake免疫療法公司的毛收入、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
HCW Biologics | $4.10 million | 17.94 | -$12.86 million | N/A | N/A |
MoonLake Immunotherapeutics | N/A | N/A | -$4.54 million | N/A | N/A |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
HCW生物製品 | 410萬美元 | 17.94 | -1,286萬元 | 不適用 | 不適用 |
月湖免疫療法 | 不適用 | 不適用 | -454萬元 | 不適用 | 不適用 |
MoonLake Immunotherapeutics has lower revenue, but higher earnings than HCW Biologics.
與HCW Biologics相比,MoonLake免疫療法的收入較低,但收益較高。
Summary
摘要
MoonLake Immunotherapeutics beats HCW Biologics on 5 of the 9 factors compared between the two stocks.
在比較兩隻股票的9個因素中,月湖免疫治療公司在5個方面擊敗了HCW Biologics。
About HCW Biologics
關於HCW生物製品公司
(Get Rating)
(獲取評級)
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
HCW生物製藥公司是一家臨牀前階段的生物製藥公司,專注於發現和開發針對慢性、低級別炎症和年齡相關疾病的新型免疫療法。該公司的主導產品包括HCW9218,這是一種可注射免疫療法,用於治療胰腺癌、卵巢癌、乳腺癌、前列腺癌和結直腸癌以及肺纖維化患者;以及HCW9302,用於治療自身免疫性疾病,如斑禿和代謝性疾病。它還開發了HCW9201,這是一種基於細胞的療法,正在進行第二階段的臨牀試驗,用於治療復發/難治性急性髓系白血病患者;以及HCW9206,用於治療急性髓系白血病。該公司成立於2018年,總部位於佛羅裏達州米拉馬爾。
About MoonLake Immunotherapeutics
關於月湖免疫療法
(Get Rating)
(獲取評級)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
月湖免疫治療公司是一家臨牀階段的生物製藥公司,致力於開發治療方法。該公司正在開發Sonelokimab,這是一種用於治療炎症的新型研究納米體療法。該公司正在進行化膿性汗腺炎、牛皮癬關節炎、強直性脊柱炎或放射學軸性脊柱炎的第二階段試驗。月湖免疫療法公司成立於2021年,總部設在瑞士祖格。
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《HCW生物製品日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對HCW Biologics和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧